Previous Article | Next Article ![]()
Molecular and Cellular Biology, May 2001, p. 3159-3165, Vol. 21, No. 9
Department of Immunology, Schering-Plough
Research Institute, Kenilworth, New Jersey 07033
Received 25 October 2000/Returned for modification 8 January
2001/Accepted 29 January 2001
Fractalkine (CX3CL1) is the first described
chemokine that can exist either as a soluble protein or as a
membrane-bound molecule. Both forms of fractalkine can mediate
adhesion of cells expressing its receptor, CX3CR1. This
activity, together with its expression on endothelial cells, suggests
that fractalkine might mediate adhesion of leukocytes to
the endothelium during inflammation. Fractalkine is also highly
expressed in neurons, and its receptor, CX3CR1, is
expressed on glial cells. To determine the biologic role of
fractalkine, we used targeted gene disruption to generate fractalkine-deficient mice. These mice did not exhibit overt
behavioral abnormalities, and histologic analysis of their brains did
not reveal any gross changes compared to wild-type mice. In addition, these mice had normal hematologic profiles except for a decrease in the
number of blood leukocytes expressing the cell surface marker F4/80.
The cellular composition of their lymph nodes did not differ
significantly from that of wild-type mice. Similarly, the responses of
fractalkine The trafficking of blood leukocytes
is mediated primarily by two major classes of molecules: cell adhesion
molecules, including selectins and integrins, and chemotactic factors,
such as the chemokines (4). Chemokines (chemotactic
cytokines) are low-molecular-weight, secreted proteins that are defined
by their ability to induce directed migration (chemotaxis) of cells
expressing an appropriate chemokine receptor(s) (28). The
ability of individual chemokines to effect cell migration in vivo is
well established (reviewed in reference 28), and recent
data suggest that different chemokines have different functions in
vivo. For example, some chemokines are required for constitutive
trafficking of immune cells through lymphoid tissues (11,
12), whereas others recruit effector cells to sites of infection
(7) or regulate immune responses (15).
Chemokines may be involved at various stages of the cell recruitment
process. First, some chemokines can activate integrins on the surface
of leukocytes, resulting in the firm adhesion of these cells to the
vascular endothelium (6). Second, chemokines are thought
to participate in directing the migration of cells once they exit the
vasculature, perhaps by establishing a concentration gradient within
that tissue. A third mechanism of chemokine action was immediately
suggested by the discovery of fractalkine (1), a
multidomain molecule that includes a chemokine region, a mucin-like stalk, and an 18-amino-acid stretch of hydrophobic residues that is
predicted to span the cell membrane. The ability of fractalkine to be presented on the cell surface suggests that this chemokine might
directly mediate cell-cell interactions. The expression of
fractalkine on endothelial cells (13) and its
upregulation by proinflammatory mediators such as tumor necrosis factor
and interleukin-1 (1) further suggest that
fractalkine might mediate adhesion of leukocytes expressing its
receptor to inflamed endothelium. Indeed, T cells and monocytes which
express that receptor, CX3CR1, adhere to monolayers of
fractalkine-expressing HEK293 cells under static conditions
(1). Furthermore, cells expressing CX3CR1 also
bind to fractalkine-coated slides under flow conditions via a
mechanism that is independent of CX3CR1 signaling and
integrin activation (10, 17).
Fractalkine can also exist as a soluble, 95-kDa
glycoprotein that results from cleavage of the full-length
protein at a dibasic motif (Thr-Arg-Arg-Gln) situated adjacent to the
membrane-binding domain. In vitro, this soluble form of human
fractalkine has potent chemoattractant activity for the same
cell types that adhere to monolayers expressing the membrane-bound form
(1). Soluble fractalkine also induces cell
adhesion but, unlike the membrane-bound form, does so by an
integrin-dependent mechanism that requires signaling through
CX3CR1 (14). The biologically relevant actions of these two forms of fractalkine are not yet known.
Murine fractalkine has 67% identity at the amino acid level
with the human protein and has the same general structural features as
the human protein (29), which was recently assigned the
name CX3CL1, according to the new nomenclature system for human
chemokines (31). However, unlike human
fractalkine, the soluble murine form of fractalkine may
be chemotactic to both neutrophils and T cells in vitro
(27). The highest expression of murine fractalkine is seen in the brain (27, 29). Although
fractalkine was initially reported to be expressed by glial
cells in mouse brain (27), subsequent studies of rat and
mouse brain indicated that the primary source of fractalkine is
neurons (16, 30), particularly in the olfactory bulb,
cerebral cortex, and hippocampus. By contrast, CX3CR1 is
primarily expressed in astrocytes and microglia throughout the brain
(16, 25). Recently, it was demonstrated that
fractalkine can induce microglial cell migration and activation
(16, 23) and that it can inhibit Fas-mediated microglial
cell death in vitro (2). Together, these data suggest that
neurons might communicate with glial cells through this ligand-receptor
pair, thereby assisting in the formation of neuronal networks or
controlling cell survival.
Organs other than the brain that express murine fractalkine
include the intestine, kidney, heart, brain, lung, skeletal muscle, and
pancreas (1). The expression in the intestine suggests a
possible role of fractalkine in mucosal immune responses.
Epithelial cells of the small and large intestine have been identified
as sources of human fractalkine, and levels of this chemokine
are increased in Crohn's disease (24). The human
fractalkine receptor CX3CR1 is expressed in the
intraepithelial lymphocytes found in the epithelial lining of the gut
(24). This expression of fractalkine and
CX3CR1 in adjacent cell types suggests that one function of fractalkine might be to control the position and number of
lymphocytes near the epithelium in both healthy and inflamed intestinal tissue.
The cell types and organs that express fractalkine suggest
several hypothetical functions for this chemokine, including possible roles in neuronal network organization or survival, adherence of
leukocytes to endothelium, and the initiation of contact between dendritic cells and lymphocytes. To directly investigate biologic requirements for fractalkine, we generated
fractalkine-deficient (fractalkine Generation of fractalkine
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.9.3159-3165.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Generation and Analysis of Mice Lacking the
Chemokine Fractalkine

![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
/
mice to a variety of
inflammatory stimuli were indistinguishable from those of wild-type mice.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
/
) mice by targeted gene
disruption. Here, we report that these mice develop normally and have
normal migration of leukocytes to lymphoid tissue and peripheral sites
in several models of inflammation.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
/
mice.
Three bacteriophage P1 clones containing the genomic copy of
the mouse fractalkine gene were isolated from a
mouse 129/ola embryonic stem (ES) cell genomic library (Incyte
Genomics, Inc., St. Louis, Mo.) using PCR primers corresponding to the
murine fractalkine gene
(5'-ACAGACGCTTCTGTGCTGA-3' and
5'-TCCAAAGCAAGGTCTTCCA-3'). Two overlapping fragments
containing the mouse gene were identified by Southern blotting of
EcoRI- and XbaI-digested P1 plasmid DNA using a
211-bp PCR-generated probe labeled with [32P]dCTP (3,000 Ci/mmol; Amersham Pharmacia Biotech, Piscataway, N.J.) by random
priming (Megaprime DNA Labeling System; Amersham Pharmacia Biotech).
These fragments were subcloned into pBluescript (Stratagene, La Jolla,
Calif.) and analyzed by DNA sequencing and restriction enzyme analysis.
A DNA vector designed to remove the entire coding region of the
fractalkine gene was constructed. This targeting
vector (Fig. 1A) was electroporated into
129SvEv-derived ES cells, and colonies resistant to both ganciclovir
and G418 were picked and expanded for DNA analysis. DNAs from these
colonies were screened for targeted fractalkine
genes by a PCR-based strategy using one primer, PCR1
(5'-CCAGGCTGGCTATGGTCCAACTG-3'), corresponding to a region
upstream of the fractalkine DNA and another primer, PCR2 (5'-TGGCGGACCGCTATCAGGAC-3'), corresponding to the
neomycin resistance gene (neo). Of 1,774 ES cell clones
analyzed, 6 yielded the 1.5-kb diagnostic PCR amplification product.
The predicted structures of the targeted fractalkine
loci (Fig. 1C) in the PCR-positive cells were confirmed by Southern
blotting using probes prepared from DNA located 5' and 3' to the
fractalkine locus. Cells from several correctly
targeted ES cell lines were injected into C57BL/6 blastocysts to
generate chimeric mice. Fractalkine-heterozygous (+/
)
offspring were identified by a PCR-based screening strategy using three
oligonucleotide primers corresponding to the region of homology, the
neo gene, and the deleted region of the
fractalkine gene. These mice were interbred to
generate fractalkine-null (
/
) mice.

View larger version (61K):
[in a new window]
FIG. 1.
Gene targeting of fractalkine. (A)
Targeting vector. Thick lines represent regions of homology to
fractalkine. The restriction enzyme sites used to
subclone these regions are indicated; RV, EcoRV; RI,
EcoRI; B, BglI; X, XbaI. (B) Wild-type
fractalkine locus. Black rectangles represent exons;
transcription is from left to right. The EcoRV fragment
diagnostic of the wild-type locus (6 kb) is shown. (C)
fractalkine targeted locus. The positions of the
oligonucleotide primers (PCR1 and PCR2) used to screen targeted ES
cells are indicated, as is the EcoRV fragment diagnostic of
the targeted locus. The arrow indicates the transcriptional direction
of neo. (D) Northern blot analysis of
fractalkine RNA from the brain of a wild-type (+/+)
mouse and a fractalkine
/
mouse. The
ethidium bromide-stained gel is shown to demonstrate equal loading of
RNA samples. (E) Immunohistochemical analysis of fractalkine in
the brain of a wild-type and a
fractalkine
/
mouse. Dark-staining
regions represent cells producing fractalkine protein; neurons
of the wild-type mouse are stained, but not those from the
fractalkine
/
mouse.
Histochemistry, immunohistochemistry, and in situ hybridization. Tissues were either fresh frozen for cryosection or fixed, processed for paraffin sections, and stained with hematoxylin and eosin. For immunostaining, fresh frozen sections were fixed with acetone. A monoclonal antifractalkine antibody was a generous gift from John Abrams (DNAX). Antibody binding was amplified using a Vectastain Elite ABC kit and detected with a diaminobenzidine substrate kit (Vector Laboratories, Burlingame, Calif.). Hematoxylin was used to counterstain the sections. In situ hybridization was carried out as described (22). Sense and antisense 33P-labeled RNA probes were transcribed using T7 or T3 polymerase (Roche Molecular Biochemicals, Indianapolis, Ind.) from a plasmid containing fractalkine cDNA from nucleotides 1786 to 2299.
Mice. Mice were generally used between 6 and 12 weeks of age. Age- and gender-matched control mice of the same 129SvEv and C57BL/6 mixed genetic background were either bred in-house or purchased from Jackson Labs (Bar Harbor, Maine). All experiments with animals were conducted according to the Schering-Plough guidelines for animal care.
Experimental peritonitis. Mice were injected intraperitoneally with 1.5 ml of thioglycolate (Microbiology Systems, Cockeysville, Md.). At 25 and 72 h postinjection, the contents of the peritoneum were lavaged by injection of 8 ml of phosphate-buffered saline (PBS). Total cells were determined from an aliquot of the lavage from each of five mice per experimental group. Smears of the cells were also dried, fixed with acetone, and stained with Protocol Hema Solutions I and II (Biochemical Sciences, Swedesboro, N.J.) according to the manufacturer's specifications. Differential counts were determined by microscopic analysis.
DTH. To determine delayed-type hypersensitivity (DTH), mice were injected subcutaneously at two sites on the dorsal flank with 0.1 ml of complete Freund's adjuvant containing 100 µg of keyhole limpet hemocyanin (KLH). Seven days postimmunization, the mice were injected in the subplantar region of the hind paw with 200 µg of KLH in 25 µl of PBS. Calipers were used to measure paw thickness at 24-h intervals postchallenge. Ten mice were used in each experimental group, and the experiment was done three times.
Flow cytometric analysis.
Cells from the epithelium and
lamina propria of the intestinal mucosa were prepared as described
previously (8). These cells were blocked with 5 µg of Fc
Block (PharMingen, San Diego, Calif.) per ml, 300 µg of mouse
immunoglobulin G (Pierce, Rockford, Ill.) per ml, and 10% rat serum
(Pierce) and then stained with phycoerythrin- or fluorescein
isothiocyanate-conjugated monoclonal antibodies directed against CD4,
CD8
, CD8
, CD3, CD11c, CD45, B220, Gr-1, NK1.1, T-cell receptors
alpha and beta (TCR
), and TCR
(PharMingen). Cells were
gated on CD45, and data were collected on a FACScan (Becton Dickinson,
San Jose, Calif.) and analyzed using CellQuest software. The total cell
number for each population was calculated based on total cells
recovered, percent CD45 cells, and percent CD45-gated cells staining
with the various antibodies.
DSS-induced enterocolitis.
Ten
fractalkine
/
mice and 10 age- and
gender-matched wild-type control mice were provided with water
containing either 3.5 or 5% dextran sulfate sodium (DSS) for 7 days.
The mice were weighed daily and examined for the presence of blood in
the perianal area. After 7 days of treatment, the DSS-containing water
was replaced with regular water for an additional 21 days. The animals
were weighed daily for the first 7 days and once a week thereafter. All
experimental mice were fasted overnight on day 27. On the following
morning, the cecum together with the adjacent pieces of jejunum and
proximal colon were collected in addition to the distal colon and
mesenteric lymph nodes. Ten mice were used in each experimental group.
This experiment was done three times.
Challenge with Listeria monocytogenes.
Cultures
of L. monocytogenes (strain EGD) were grown as described
previously (9). Briefly, bacteria were grown
overnight in Trypticase soy broth, and the concentration of the
culture was determined by spectrophotometric analysis. Bacteria were
suspended in sterile, nonbacteriostatic saline at 105
CFU/ml, and equal volumes (0.1 ml) were injected into the lateral tail veins of experimental mice. At 48 h postinfection, spleens were collected and strained through a 40-µl nylon mesh in PBS containing 0.1% Triton X-100. Serial dilutions of this homogenate were
spread onto Trypticase soy agar plates. Colonies were counted the
following day. For survival experiments, 10 wild-type and 8 fractalkine
/
mice were used. For CFU
counts, 10 mice per group were used. Statistical significance was
assessed using Student's t test.
| |
RESULTS AND DISCUSSION |
|---|
|
|
|---|
Analysis of fractalkine expression in wild-type mice. We first used Northern blot analysis to investigate fractalkine expression in 19 different mouse tissues. As reported previously by others, very high levels of fractalkine expression were seen in the brain and spinal cord, with lower levels seen in kidney, large and small intestine, lung, uterus, ovary, and adrenal gland. On prolonged exposure of the autoradiograph, fractalkine expression was detected in almost all tissues (data not shown).
Generation of fractalkine
/
mice.
A gene-targeting vector (Fig. 1A) was constructed using
fractalkine genomic DNA. This vector was designed so
that after its recombination with the fractalkine
locus (Fig. 1B), the entire coding region of
CX3C would be excised (Fig. 1C). Intercrosses of
fractalkine+/
mice derived from
chimeras yielded wild-type
(fractalkine+/+),
fractalkine+/
, and
fractalkine
/
mice in the expected
Mendelian ratio of 1:2:1. The
fractalkine
/
mice appeared healthy
and were fertile. To determine if any abnormalities would become
apparent in older mice, 10 fractalkine
/
mice were allowed to
reach 18 months of age. No overt abnormalities were observed.
Analysis of fractalkine RNA and
fractalkine protein in gene-targeted mice.
To test whether
the fractalkine
/
mice were able to
produce fractalkine RNA, we performed Northern blot
analysis of mRNA prepared from brains of wild-type and
fractalkine
/
mice.
fractalkine RNA was readily detected in wild-type
brains, but was undetectable in brains of
fractalkine
/
mice (Fig. 1D).
/
mice, using an antibody directed against fractalkine. In
wild-type mice, no immunoreactive protein was seen in glial cells,
although it was abundant in neurons (Fig. 1E). These data are in
contrast to the fractalkine expression in glial
cells that was originally reported but consistent with more recent
reports of neuronal fractalkine expression in the
mouse (30) and rat (23, 25). No
fractalkine was detected in the brains of
fractalkine
/
mice.
Histologic and flow cytometric analyses of
fractalkine
/
mice.
To
determine whether the absence of fractalkine results in
abnormalities of any major tissue (most of which express
fractalkine), we examined formalin-fixed tissue sections of
fractalkine
/
mice by light
microscopy. No inflammation or developmental abnormalities were noted
in lung, kidney, brain, heart, thymus, stomach, small and large
intestine, spine, lymph nodes, or liver. Thus, fractalkine is
not required for the development of these organs.
/
mice. This analysis did
not reveal statistically significant differences between
fractalkine
/
mice and wild-type mice
with regard to the total white blood cell count, red blood cell number,
hematocrit, or percentage or absolute number of neutrophils,
lymphocytes, monocytes, eosinophils, and basophils (Table
1).
|
/
mice
was a significant decrease in F4/80-expressing blood monocytes (Table
2). Taken together, these results
demonstrate that fractalkine is not required for normal
development of any major leukocyte subset and that these cells migrate
normally to the tissues examined.
|
Response to thioglycolate.
As the decrease in circulating
F4/80-expressing monocytes was the only abnormality seen in
unchallenged fractalkine
/
mice, we
next investigated the requirement for fractalkine in inflammatory responses. Injection of thioglycolate into the peritoneum of mice induces an inflammatory response characterized by an influx of
mononuclear cells into the peritoneum at 24 h postchallenge. Chemokines are required for this recruitment (3, 5, 20, 21). To determine whether fractalkine is required for
this influx, we challenged both wild-type and
fractalkine
/
mice with thioglycolate
and counted the number of inflammatory cells in the peritoneal exudate.
There were no significant differences in the number of total cells or
mononuclear cells between the two groups of mice at either 24 h
(Fig. 2A) or 72 h (Fig. 2B) postchallenge. Thus, at least in this model, fractalkine is not required for the recruitment of mononuclear cells to the peritoneum.
|
DTH.
To determine if fractalkine is required for a
T-lymphocyte-mediated DTH response, an experiment was performed
in which mice were immunized by a subcutaneous injection of KLH
and challenged 7 days later by injection of KLH into the footpad.
Measurements of paw swelling in the challenged mice did not reveal
significant differences between
fractalkine
/
and wild-type mice
(Fig. 3), indicating that
fractalkine
/
mice have no gross
defect in T-cell-mediated immune responses.
|
Analysis of small intestine.
The expression of
fractalkine and CX3CR1 by intestinal epithelial
cells and intraepithelial lymphocytes (24), respectively, suggests that fractalkine might mediate physiologic trafficking of lymphocytes to the intestine. To test this possibility, we prepared
lymphocytes from the epithelium and lamina propria and analyzed various
cell lineages by flow cytometry. Of several T-cell lineages analyzed,
the only difference between wild-type and
fractalkine
/
mice was a significant
and reproducible increase in the percentage of CD4+ cells
in the gut epithelium (Fig. 4A). An
increase in CD4+ CD8+ cells was also seen, but
this difference was not statistically significant. No differences were
seen in the leukocyte populations in the lamina propria. These results
demonstrate that fractalkine is not required for the normal,
physiologic trafficking of most leukocytes to the small intestine.
|
/
mice was slightly lower
than that of wild-type mice during the early phase of the experiment
(Fig. 4B), but this difference was not statistically significant or
seen in all experiments. Moreover, no marked differences between
wild-type and fractalkine
/
mice were
seen during the weight loss or weight gain phases of the experiment
(Fig. 4C). Thus, fractalkine is not required for the induction
of enterocolitis or for recovery of mice from the acute phase of the disease.
Response of fractalkine
/
mice
to L. monocytogenes.
Monocytes express
CX3CR1 and migrate in response to soluble
fractalkine. As the number of circulating F4/80-positive cells was decreased in fractalkine
/
mice,
we considered the possibility that fractalkine might mediate recruitment of monocytes or macrophages to infected tissue. To test
whether macrophage function was impaired in
fractalkine
/
mice, we infected
them with L. monocytogenes. No significant differences
between wild-type and fractalkine
/
mice were seen in their abilities to survive relatively low doses (3 × 103) of listeriae over 2 weeks (Fig.
5A). We also performed an analysis of
splenic CFU at 48 h postinfection. This time point was chosen because clearance of this facultative intracellular bacterial pathogen
48 h postinfection is mediated primarily by activated macrophages
(reviewed in reference 26). Analysis of the listeria CFU
present in spleens of infected mice did not reveal statistically significant differences between wild-type and
fractalkine
/
mice (Fig. 5B). Thus,
fractalkine is not required for macrophage function in this
model.
|
/
mice and demonstrated
that they do not produce fractalkine RNA or
fractalkine protein in the brain. Despite the absence of this
protein, fractalkine
/
mice do not
have histologic abnormalities in any major organs (including the
brain), and hematopoietic lineages in blood and lymphoid tissue are
essentially normal. Likewise,
fractalkine
/
mice do not exhibit any
overt behavioral abnormalities. These preliminary findings are similar
to data described by Jung et al., who used targeted gene disruption to
generate mice lacking CX3CR1 (19). Those
investigators were unable to demonstrate differences between
CX3CR1
/
mice and wild-type mice
with regard to monocyte recruitment, dendritic cell differentiation and
migration, or their microglial response to facial nerve injury. Thus,
the biological role of fractalkine remains an enigma, and
additional studies will be required to uncover any biologic requirement
for this structurally fascinating chemokine and its receptor.
| |
ACKNOWLEDGMENTS |
|---|
We thank Susan Abbondanzo, Petronio Zalamea, Channa Young, Margaret Monahan, and Linda Hamilton for excellent technical assistance and Albert Zlotnik and Fernando Bazan for helpful discussions and for the murine fractalkine cDNA.
The first two authors contributed equally to this work.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Immunology, Schering-Plough Research Institute, 2015 Galloping Hill Rd., Kenilworth, NJ 07033. Phone: (908) 740-3088. Fax: (908) 740-3084. E-mail: sergio.lira{at}spcorp.com.
Present address: Division of Pulmonary and Critical Care Medicine,
Duke University Medical Center, Durham, NC 27710.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Bazan, J. F., K. B. Bacon, G. Hardiman, W. Wang, K. Soo, D. Rossi, D. R. Greaves, A. Zlotnik, and T. J. Schall. 1997. A new class of membrane-bound chemokine with a CX3C motif. Nature 385:640-644[CrossRef][Medline]. |
| 2. |
Boehme, S. A.,
F. M. Lio,
D. Maciejewski-Lenoir,
K. B. Bacon, and P. J. Conlon.
2000.
The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia.
J. Immunol.
165:397-403 |
| 3. | Boring, L., J. Gosling, S. W. Chensue, S. L. Kunkel, R. V. Farese, Jr., H. E. Broxmeyer, and I. F. Charo. 1997. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Investig. 100:2552-2561[Medline]. |
| 4. | Butcher, E. C., and L. J. Picker. 1996. Lymphocyte homing and homeostasis. Science 272:60-66[Abstract]. |
| 5. |
Cacalano, G.,
J. Lee,
K. Kikly,
A. M. Ryan,
S. Pitts-Meek,
B. Hultgren,
W. I. Wood, and M. W. Moore.
1994.
Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog.
Science
265:682-684 |
| 6. |
Campbell, J. J.,
J. Hedrick,
A. Zlotnik,
M. A. Siani,
D. A. Thompson, and E. C. Butcher.
1998.
Chemokines and the arrest of lymphocytes rolling under flow conditions.
Science
279:381-384 |
| 7. |
Cook, D. N.,
M. A. Beck,
T. M. Coffman,
S. L. Kirby,
J. F. Sheridan,
I. B. Pragnell, and O. Smithies.
1995.
Requirement of MIP-1 alpha for an inflammatory response to viral infection.
Science
269:1583-1585 |
| 8. | Cook, D. N., D. M. Prosser, R. Forster, J. Zhang, N. A. Kuklin, S. J. Abbondanzo, X. D. Niu, S. C. Chen, D. J. Manfra, M. T. Wiekowski, L. M. Sullivan, S. R. Smith, H. B. Greenberg, S. K. Narula, M. Lipp, and S. A. Lira. 2000. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity 12:495-503[CrossRef][Medline]. |
| 9. |
Cook, D. N.,
O. Smithies,
R. M. Strieter,
J. A. Frelinger, and J. S. Serody.
1999.
CD8+ T cells are a biologically relevant source of macrophage inflammatory protein-1 alpha in vivo.
J. Immunol.
162:5423-5428 |
| 10. |
Fong, A. M.,
L. A. Robinson,
D. A. Steeber,
T. F. Tedder,
O. Yoshie,
T. Imai, and D. D. Patel.
1998.
Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow.
J. Exp. Med.
188:1413-1419 |
| 11. | Forster, R., A. E. Mattis, E. Kremmer, E. Wolf, G. Brem, and M. Lipp. 1996. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87:1037-1047[CrossRef][Medline]. |
| 12. | Forster, R., A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Muller, E. Wolf, and M. Lipp. 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99:23-33[CrossRef][Medline]. |
| 13. | Foussat, A., A. Coulomb-L'Hermine, J. Gosling, R. Krzysiek, I. Durand-Gasselin, T. Schall, A. Balian, Y. Richard, P. Galanaud, and D. Emilie. 2000. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur. J. Immunol. 30:87-97[CrossRef][Medline]. |
| 14. |
Goda, S.,
T. Imai,
O. Yoshie,
O. Yoneda,
H. Inoue,
Y. Nagano,
T. Okazaki,
H. Imai,
E. T. Bloom,
N. Domae, and H. Umehara.
2000.
CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms.
J. Immunol.
164:4313-4320 |
| 15. | Gu, L., S. Tseng, R. M. Horner, C. Tam, M. Loda, and B. J. Rollins. 2000. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404:407-411[CrossRef][Medline]. |
| 16. |
Harrison, J. K.,
Y. Jiang,
S. Chen,
Y. Xia,
D. Maciejewski,
R. K. McNamara,
W. J. Streit,
M. N. Salafranca,
S. Adhikari,
D. A. Thompson,
P. Botti,
K. B. Bacon, and L. Feng.
1998.
Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia.
Proc. Natl. Acad. Sci. USA
95:10896-10901 |
| 17. |
Haskell, C. A.,
M. D. Cleary, and I. F. Charo.
1999.
Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction: rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation.
J. Biol. Chem.
274:10053-10058 |
| 18. | Imai, T., K. Hieshima, C. Haskell, M. Baba, M. Nagira, M. Nishimura, M. Kakizaki, S. Takagi, H. Nomiyama, T. J. Schall, and O. Yoshie. 1997. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91:521-530[CrossRef][Medline]. |
| 19. |
Jung, S.,
J. Aliberti,
P. Graemmel,
M. J. Sunshine,
G. W. Kreutzberg,
A. Sher, and D. R. Littman.
2000.
Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion.
Mol. Cell. Biol.
20:4106-4114 |
| 20. |
Kurihara, T.,
G. Warr,
J. Loy, and R. Bravo.
1997.
Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor.
J. Exp. Med.
186:1757-1762 |
| 21. |
Kuziel, W. A.,
S. J. Morgan,
T. C. Dawson,
S. Griffin,
O. Smithies,
K. Ley, and N. Maeda.
1997.
Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2.
Proc. Natl. Acad. Sci. USA
94:12053-12058 |
| 22. |
Lugo, D.,
J. Roberts, and J. Pintar.
1989.
Analysis of proopiomelanocortin gene expression during prenatal development of the rat pituitary gland.
Mol. Endocrinol.
3:1313-1324 |
| 23. |
Maciejewski-Lenoir, D.,
S. Chen,
L. Feng,
R. Maki, and K. B. Bacon.
1999.
Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia.
J. Immunol.
163:1628-1635 |
| 24. |
Muehlhoefer, A.,
L. J. Saubermann,
X. Gu,
K. Luedtke-Heckenkamp,
R. Xavier,
R. S. Blumberg,
D. K. Podolsky,
R. P. MacDermott, and H. C. Reinecker.
2000.
Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa.
J. Immunol.
164:3368-3376 |
| 25. | Nishiyori, A., M. Minami, Y. Ohtani, S. Takami, J. Yamamoto, N. Kawaguchi, T. Kume, A. Akaike, and M. Satoh. 1998. Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia? FEBS Lett. 429:167-172[CrossRef][Medline]. |
| 26. | North, R. J., P. L. Dunn, and J. W. Conlan. 1997. Murine listeriosis as a model of antimicrobial defense. Immunol. Rev. 158:27-36[CrossRef][Medline]. |
| 27. | Pan, Y., C. Lloyd, H. Zhou, S. Dolich, J. Deeds, J. A. Gonzalo, J. Vath, M. Gosselin, J. Ma, B. Dussault, E. Woolf, G. Alperin, J. Culpepper, J. C. Gutierrez-Ramos, and D. Gearing. 1997. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 387:611-617[CrossRef][Medline]. (Erratum, 389:100.) |
| 28. |
Rollins, B. J.
1997.
Chemokines.
Blood
90:909-928 |
| 29. | Rossi, D. L., G. Hardiman, N. G. Copeland, D. J. Gilbert, N. Jenkins, A. Zlotnik, and J. F. Bazan. 1998. Cloning and characterization of a new type of mouse chemokine. Genomics 47:163-170[CrossRef][Medline]. |
| 30. | Schwaeble, W. J., C. M. Stover, T. J. Schall, D. J. Dairaghi, P. K. Trinder, C. Linington, A. Iglesias, A. Schubart, N. J. Lynch, E. Weihe, and M. K. Schafer. 1998. Neuronal expression of fractalkine in the presence and absence of inflammation. FEBS Lett. 439:203-207[CrossRef][Medline]. |
| 31. | Zlotnik, A., and O. Yoshie. 2000. Chemokines: a new classification system and their role in immunity. Immunity 12:121-127[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»